INmune Bio Inc. Common stock
INMBINmune Bio Inc. (INMB) is a clinical-stage biotechnology company focused on developing novel immunotherapies to treat neurodegenerative diseases, cancer, and infectious diseases. The company's approach involves targeting specific immune pathways to modulate the immune response and improve patient outcomes. INmune Bio aims to advance therapies that leverage the body's immune system to fight various diseases more effectively.
Company News
A peer-reviewed study published in Cytotherapy explores the potential of mesenchymal stromal cell (MSC) therapies, focusing on systemic delivery, local delivery methods, and in vivo persistence of cell treatments.
Inmune Bio, a biopharmaceutical company, held its annual stockholders meeting, resulting in the re-election of its board of directors and the ratification of its independent auditor for the upcoming fiscal year.
Upgrades For Banco Latinoamericano de Comercio Exterior SA (NYSE:BLX), Credit Suisse upgraded the previous rating of Neutral to Outperform. Banco Latinoamericano earned $1.02 in the first quarter, compared to $0.31 in the year-ago quarter. The stock has a 52-week-high of $20.48 and a 52-week-low of $12.59. At the end of the last trading period, B...
The mean of analysts' price targets for INmune Bio, Inc. (INMB) points to a 98.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
INMB earnings call for the period ending June 30, 2022.
